Alzheimer Disease CRISPR Knockout Cell Models for Drug Discovery

Alzheimer disease (AD) is the most common cause of dementia, affecting an estimated 55 million people worldwide as of 2023 (WHO). The global prevalence is projected to reach 78 million by 2030. AD is the seventh leading cause of death globally, with a 5-year survival rate after diagnosis of approximately 20-40% (NCI). Key risk factors include age (over 65 years), family history, apolipoprotein E (APOE) ε4 allele, cardiovascular conditions, and traumatic brain injury. The economic burden exceeds $1 trillion annually, driven by long-term care and lost productivity.

AD is ideal for mechanistic studies due to its well-defined pathological hallmarks: extracellular amyloid-beta (Aβ) plaques and intracellular tau neurofibrillary tangles. The disease is genetically heterogeneous, with rare autosomal dominant mutations (APP, PSEN1, PSEN2) and common risk variants (APOE, TREM2, CLU). Public datasets such as the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Religious Orders Study and Memory and Aging Project (ROSMAP) provide rich clinical and multi-omics data. Open questions include the role of neuroinflammation, synaptic dysfunction, and the interplay between Aβ and tau pathology.

AD is not a cancer, but its pathogenesis involves several key pathways:

• • Amyloidogenic pathway: Sequential cleavage of amyloid precursor protein (APP) by beta-secretase (BACE1) and gamma-secretase (presenilin complex) generates Aβ peptides (Aβ40, Aβ42). Aβ42 oligomers aggregate into plaques, triggering neurotoxicity.
• • Tau hyperphosphorylation: Hyperphosphorylated tau dissociates from microtubules, aggregates into paired helical filaments, and forms neurofibrillary tangles, disrupting axonal transport and synaptic function.
• • Neuroinflammation: Activated microglia and astrocytes release pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), exacerbating neuronal damage.
• • Oxidative stress and mitochondrial dysfunction: Accumulation of reactive oxygen species (ROS) and impaired mitochondrial dynamics contribute to synaptic loss and cell death.

Data from ClinVar, NCBI Gene, and large GWAS studies (e.g., Lambert et al., 2013).

• • MAPK/ERK pathway: Hyperactivation in response to Aβ oligomers leads to tau phosphorylation and synaptic dysfunction.
• • PI3K/AKT/mTOR pathway: Dysregulated in AD, contributing to impaired autophagy and protein aggregation.
• • Wnt/β-catenin pathway: Reduced signaling increases tau phosphorylation and Aβ production.
• • NF-κB pathway: Activated by Aβ and inflammatory cytokines, promoting neuroinflammation.
• • CREB signaling: Impaired in AD, reducing synaptic plasticity and memory formation.

Organoids offer a more physiologically relevant 3D environment, enabling study of cell-cell interactions and network activity.

• • Transgenic mouse models: APP/PS1 (co-express human APP Swedish mutation and PSEN1 ΔE9), 5xFAD (five familial mutations), Tau P301S (tauopathy).
• • Knock-in mouse models: AppNL-G-F (humanized APP with Swedish, Iberian, Arctic mutations), MAPT knock-in (human tau).
• • Induced models: Stereotaxic injection of Aβ oligomers or tau seeds into wild-type mice.
• • Zebrafish models: Transgenic lines expressing human APP or tau for high-throughput screening.
• • Non-human primates: Aged rhesus macaques naturally develop Aβ plaques and tau tangles.

CRISPR-Cas9 gene editing enables precise introduction of AD-associated mutations or knockouts in human cell lines. Examples include:

• • APP knockout: Eliminates Aβ production; used to study APP function and alternative pathways.
• • PSEN1 ΔE9 knock-in: Models familial AD; increases Aβ42/Aβ40 ratio.
• • MAPT knockout: Removes tau; used to assess tau requirement in Aβ toxicity.
• • APOE ε4 knock-in: Replaces endogenous APOE with ε4 allele; models risk variant effects.

Commercially available, sequence-verified isogenic cell lines (e.g., SH-SY5Y, HEK293T, iPSC-derived neurons) accelerate research by providing reproducible, validated models. These tools enable controlled experiments to dissect gene function, screen drug candidates, and identify biomarkers without the variability of primary cells or animal models.

CRISPR knockout and knock-in lines validate the role of specific genes in AD pathogenesis. For example:

• • BACE1 knockout: Reduces Aβ production; confirms BACE1 as a therapeutic target.
• • TREM2 knockout: Impairs microglial phagocytosis; elucidates TREM2 function in neuroinflammation.
• • CLU knockout: Alters Aβ clearance; supports clusterin's role in amyloid metabolism.

These models allow researchers to study gene function in a controlled genetic background, essential for understanding complex polygenic interactions.

Isogenic cell pairs (e.g., wild-type vs. PSEN1 mutant) enable high-throughput screening for compounds that reduce Aβ42 levels or tau phosphorylation. For example:

• • Gamma-secretase modulators: Screened in PSEN1 knock-in cells to identify compounds that shift Aβ production toward shorter, less toxic species.
• • Tau aggregation inhibitors: Tested in MAPT P301L knock-in cells to measure aggregate formation.
• • Resistance modeling: Chronic treatment with BACE inhibitors in APP-overexpressing cells can select for resistant clones, revealing compensatory mechanisms.

CRISPR screens identify genes that modulate Aβ secretion, tau aggregation, or neuronal survival. For example:

• • Synthetic lethality screens: In APOE ε4 knock-in neurons, identify genes that when knocked out selectively kill ε4-carrying cells, revealing potential therapeutic targets.
• • Secretome analysis: Conditioned media from APP knockout vs. wild-type cells identifies novel Aβ-dependent biomarkers.
• • CRISPRa/CRISPRi screens: Genome-wide activation or repression of genes in iPSC-derived neurons identifies modifiers of tau pathology.